acne vulgaris
Conditions
Interventions
Experimental group:Chemical peel treatment with supramolecular lactic acid products
Using supramolecular lactic acid products for chemical peels treatment
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: (1) Voluntarily participate in this trial and sign the informed consent form; Agree to conduct the trial as directed by a physician throughout the study period; (2) Chinese, aged between 18 and 35 years old, male or female; (3) Meet the diagnostic criteria for acne vulgaris and the degree of lesions meets the Acne Pillsbury grade I.-III; (4) During the trial, the following items can be done: no oral or topical retinoids, no external use of other salicylic acid, fruit acid and other functional skin care products similar to the test products other than those specified in this clinical trial, no systemic or topical glucocorticoid therapy, photoelectric therapy, or chemical peels for acne treatment patients.
Exclusion criteria
Exclusion criteria: 1 Those who have not signed an informed consent form, cannot cooperate with doctors' guidance for the experiment, or cannot accurately describe their condition; 2 Pregnant or lactating women or female patients with fertility plans during the study; 3 Patients known to be allergic to the trial product or oral and topical drug ingredients involved in the trial; 4 Patients who have taken oral retinoid drugs or glucocorticoids within 4 weeks before the start of the trial; patients who have used topical retinoid drugs, phototherapy, or chemical peels for acne treatment within 2 weeks before the trial. 5 There are other obvious skin diseases on the face that may affect the efficacy evaluation, such as: actinic dermatitis, facial psoriasis, facial seborrheic dermatitis, herpes simplex, and herpes zoster; 6 Occupational acne caused by chemical substances or drug-induced acne; 7 Those with scar formation at or outside the treatment site; 8 Patients with severe cardiovascular, liver, kidney, or other systemic diseases, tumors, or mental disorders; 9 Subjects whom the investigator believes are not suitable for participation in the trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of lesion improvement Improvement rate of skin lesions;Total effective rate of treatment for 12 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigator’s Global Assessment;Water content of stratum corneum;Transepidermal Water Loss;Skin color; | — |
Countries
China
Contacts
Public ContactWu Yan
Peking University First Hospital
Outcome results
None listed